Last reviewed 2026-04-23 · How we verify

Liquid CAIV-T

Liquid CAIV-T is a live attenuated influenza vaccine administered intranasally that stimulates mucosal and systemic immune responses against influenza A and B viruses.

Liquid CAIV-T is a live attenuated influenza vaccine administered intranasally that stimulates mucosal and systemic immune responses against influenza A and B viruses. Used for Seasonal influenza prevention in children and adults aged 2-49 years.

At a glance

Mechanism of action

CAIV-T (Cold-Adapted Influenza Vaccine - Trivalent) contains temperature-sensitive, live attenuated influenza virus strains that replicate efficiently in the cooler upper respiratory tract but are unable to replicate in the warmer lower respiratory tract and systemic circulation. This restricted replication pattern triggers both mucosal IgA and systemic IgG antibody responses, as well as cell-mediated immunity, providing protection against influenza infection while minimizing systemic reactogenicity.

Approved indications

• Seasonal influenza prevention in children and adults aged 2-49 years

Common side effects

• Nasal congestion
• Runny nose
• Sore throat
• Cough
• Fever
• Myalgia

Key clinical trials

• Trial to Investigate Viral Shedding in Healthy Children Vaccinated With Vaccine Virus Liquid (CAIV-T) (PHASE2)
• Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted (CAIV-T) in Healthy Adults (PHASE3)
• Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine,(CAIV-T) (PHASE3)
• Trivalent, Live, Cold Adapted Influenza Vaccine (CAIV-T) Against Inactivated Influenza Vaccine (TIV) in Children 6-59 Months of Age (PHASE3)
• Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine(CAIV-T)in Healthy Adults Aged 18 to 59 and Healthy Adults Aged 60 Years and Older (PHASE2)
• Trial to Compare the Safety, Tolerability, and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Inactivated, Influenza Vaccine, Trivalent, Types A & B, in Adults Aged 60 Years and Older Against Culture-confirmed Influenza (PHASE3)
• A Phase II, Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine, CAIV-T in Healthy Children and Adolescents Ages 6 to Less Than 18 Years. (PHASE2)
• Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine (CAIV-T) in Healthy Children (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.